Characteristics and distinct prognostic determinants of individuals with hepatosplenic T-cell lymphoma over the past two decades

被引:0
作者
Bangolo, Ayrton [1 ]
Fwelo, Pierre [2 ]
Dey, Shraboni [1 ]
Sethi, Tanni [1 ]
Sagireddy, Sowmya [3 ]
Chatta, Jawaria [1 ]
Goel, Ashish [1 ]
Nagpaul, Sneha [1 ]
Chen, Eric Pin-Shiuan [1 ]
Saravanan, Chiranjeeve [1 ]
Gangan, Sheeja [1 ]
Thomas, Joel [1 ]
Potiguara, Sarah [1 ]
Nagesh, Vignesh K. [1 ]
Elias, Daniel [1 ]
Mansour, Charlene [1 ]
Ratnaparkhi, Prajakta H. [1 ]
Jain, Priyanshu [1 ]
Mathew, Midhun [1 ]
Porter, Taylor [1 ]
Sultan, Shadiya [1 ]
Abbisetty, Shailaja [1 ]
Tran, Linh [1 ]
Chawla, Megha [1 ]
Lo, Abraham [3 ]
Weissman, Simcha [1 ]
Cho, Christina [4 ]
机构
[1] Palisades Med Ctr, Dept Internal Med, 7600 River Rd, North Bergen, NJ 07047 USA
[2] UTHealth Sch Publ Hlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA
[3] Palisades Med Ctr, Dept Med, North Bergen, NJ 07047 USA
[4] John Theurer Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Hackensack, NJ 07601 USA
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 15卷 / 06期
关键词
Extra nodal lymphoma; Mortality; Survival; Racial disparity; Age; SURVIVAL; ENTITY;
D O I
10.5306/wjco.v15.i6.745
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive peripheral T-cell lymphoma with historically dismal outcomes, representing less than one percent of non-Hodgkin lymphomas. Given its rarity, the true incidence of HSTCL is unknown and most data have been extrapolated through case reports. To the best of our knowledge, the largest and most up to date study addressing the epidemiology and outcomes of patients with HSTCL in the United States covered a period from 1996 to 2014, with a sample size of 122 patients. AIM To paint the most updated epidemiological picture of HSTCL. METHODS A total of 186 patients diagnosed with HSTCL, between 2000 and 2017, were ultimately enrolled in our study by retrieving data from the Surveillance, Epidemiology, and End Results database. We analyzed demographics, clinical characteristics, and overall mortality (OM) as well as cancer-specific mortality (CSM) of HSTCL. Variables with a P value < 0.01 in the univariate Cox regression were incorporated into the multivariate Cox model to determine the independent prognostic factors, with a hazard ratio of greater than 1 representing adverse prognostic factors. RESULTS Male gender was the most represented. HSTCL was most common in middle-aged patients (40-59) and less common in the elderly (80+). Non-Hispanic whites (60.75%) and non-Hispanic blacks (20.97%) were the most represented racial groups. Univariate Cox proportional hazard regression analysis of factors influencing all-cause mortality showed a higher OM among non-Hispanic black patients. CSM was also higher among non-Hispanic blacks and patients with distant metastasis. Multivariate Cox proportional hazard regression analysis of factors affecting CSM revealed higher mortality in patients aged 80 or older and non-Hispanic blacks. CONCLUSION Overall, the outlook for this rare malignancy is very grim. In this retrospective cohort study of the United States population, non-Hispanic blacks and the elderly had a higher CSM. This data highlights the need for larger prospective studies to investigate factors associated with worse prognosis in one ethnic group, such as treatment delays, which have been shown to increase mortality in this racial/ethnic group for other cancers.
引用
收藏
页数:11
相关论文
共 32 条
  • [1] Abouyabis Abeer N, 2011, ISRN Hematol, V2011, P623924, DOI 10.5402/2011/623924
  • [2] ANDERSON T, 1982, CANCER-AM CANCER SOC, V50, P2708, DOI 10.1002/1097-0142(19821215)50:12<2708::AID-CNCR2820501203>3.0.CO
  • [3] 2-G
  • [4] Bangolo AI., 2023, Blood, V142, P6271
  • [5] Bangolo A, 2023, J CLIN ONCOL, V41
  • [6] Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience
    Bojanini, Leyla
    Jiang, Liuyan
    Tun, Alexander J.
    Ayala, Ernesto
    Menke, David M.
    Hoppe, Bradford
    Kharfan-Dabaja, Mohamed A.
    Tun, Han W.
    Moustafa, Muhamad Alhaj
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02) : 106 - +
  • [7] Hepatosplenic T-cell lymphoma: treatment challenges
    Bron, Dominique
    De Leval, Laurence
    Michiels, Sandra
    Wittnebel, Sebastian
    [J]. CURRENT OPINION IN ONCOLOGY, 2021, 33 (05) : 406 - 411
  • [8] Cho MW, 2018, AM J NUCL MED MOLEC, V8, P137
  • [9] EUROPEAN SCHOOL OF ONCOLOGY - MANAGEMENT OF NON-HODGKINS-LYMPHOMAS - CONCLUSIONS OF THE EUROPEAN SCHOOL OF ONCOLOGY MEETING, 1986
    COIFFIER, B
    BOSLY, A
    CALIGARISCAPPIO, F
    GISSELBRECHT, C
    PATTE, C
    SCHAADT, M
    SYMANN, M
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (11): : 1691 - 1695
  • [10] Cooke CB, 1996, BLOOD, V88, P4265